EZH2 and sarcoma: Adding further support to the clinical relevance of EZH2, we evaluated EZH2 expression with respect to overall survival within The Cancer Genome Atlas (TCGA) dataset, which showed that patients with the highest quartile of EZH2 expression was associated with significantly worse survival compared to sarcomas with the lowest quartile of EZH2 expression (Fig. 3B, p = 0.049)16.